Craig Lindsley Archives
Investigational new drug for Alzheimer’s scheduled for first study in humans
Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
Nine Vanderbilt faculty members elected AAAS fellows
Nov. 25, 2016—Nine Vanderbilt University faculty members have been elected fellows of the American Association for the Advancement of Science this year.
Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt
Aug. 15, 2016—Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.
Vanderbilt, Ono Pharmaceutical sign drug discovery agreement
Dec. 10, 2015—Vanderbilt University Medical Center and Ono Pharmaceutical Group, an international company based in Japan, have signed a drug discovery agreement.
Five VUMC faculty members on list of most frequently cited researchers
Oct. 8, 2015—Five current faculty members at Vanderbilt University Medical Center have made this year’s list of scientists whose papers have been cited most frequently by others.
Collaboration seeks to develop new therapies for bone, other diseases
Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.
Grant enhances mental illness drug research efforts
Jul. 16, 2015—Research at Vanderbilt University Medical Center aimed at developing potential new treatments for major depressive disorder, general anxiety disorder and post-traumatic stress disorder got a big boost this week from The William K. Warren Foundation of Tulsa, Oklahoma.
New strategy to combat HIV
Jun. 12, 2015—Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered.
Grant spurs schizophrenia research
Feb. 12, 2015—Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness.
Schizophrenia ‘switches’ discovered
Sep. 12, 2014—Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way.
Enzyme holds the door for influenza
Aug. 20, 2014—Compounds developed at Vanderbilt University may offer a new way to block influenza infection.
Small molecule protects kidney filter
Mar. 19, 2014—A compound identified at Vanderbilt has therapeutic potential in protecting the kidney filter barrier.
